Neukio Bio Completes $50 Million Round for Allogenic CAR-T Therapies

Shanghai Neukio Biotherapeutics completed a $50 million Series A-1 funding to support development of its cell therapy molecules, especially off-the-shelf allogenic CAR-T therapies. One year ago, Neukio raised $40 million in an Angel round. The company will use the funds to accelerate preclinical/clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, while also expanding its team and operations. The latest funding was led by CD Capital, with participation from Alwin Capital and Surplus Capital as new investors. Existing shareholders Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital also joined. More details....

Share this with colleagues: